1-12 of 12
exenatide
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparison of the Usability, Accuracy, Preference, and Satisfaction of Three Once-Weekly Glucagon-Like Peptide 1 Receptor Agonist Pen Devices in People With Type 2 Diabetes

Free
Sara A. Wettergreen, Morgan P. Stewart, Katelyn Kennedy, Jennifer M. Trujillo
Journal: Diabetes Spectrum
Diabetes Spectr 2023;36(1):5–13
https://doi.org/10.2337/ds21-0108
Published: 29 June 2022
View articletitled, Comparison of the Usability, Accuracy, Preference, and Satisfaction of Three Once-Weekly Glucagon-Like Peptide 1 Receptor Agonist Pen Devices in People With Type 2 Diabetes
Open the PDF for Comparison of the Usability, Accuracy, Preference, and Satisfaction of Three Once-Weekly Glucagon-Like Peptide 1 Receptor Agonist Pen Devices in People With Type 2 Diabetes in another window
Journal Articles

Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide

Free
Elizabeth B. Hearn, Justin J. Sherman
Journal: Diabetes Spectrum
Diabetes Spectr 2021;34(1):73–75
https://doi.org/10.2337/ds20-0033
Published: 01 February 2021
View articletitled, Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide
Open the PDF for Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide in another window
Journal Articles

Comparison of Usability, Accuracy, Preference, and Satisfaction Among Three Once-Weekly GLP-1 Receptor Agonist Pen Devices

Open Access
Anna Y. Zhou, Jennifer M. Trujillo
Journal: Diabetes Spectrum
Diabetes Spectr 2018;31(4):359–366
https://doi.org/10.2337/ds17-0048
Published: 01 November 2018
View articletitled, Comparison of Usability, Accuracy, Preference, and Satisfaction Among Three Once-Weekly GLP-1 Receptor Agonist Pen Devices
Open the PDF for Comparison of Usability, Accuracy, Preference, and Satisfaction Among Three Once-Weekly GLP-1 Receptor Agonist Pen Devices in another window
Journal Articles

Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States

Open Access
Anita M. Loughlin, Qing Qiao, Anthony P. Nunes, Stephen M. Ezzy, Laura Yochum, C. Robin Clifford, Robert V. Gately, David D. Dore, John D. Seeger
Journal: Diabetes Spectrum
Diabetes Spectr 2018;31(2):129–137
https://doi.org/10.2337/ds16-0081
Published: 01 May 2018
View articletitled, Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States
Open the PDF for Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States in another window
Journal Articles

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes

Open Access
Deborah Hinnen
Journal: Diabetes Spectrum
Diabetes Spectr 2017;30(3):202–210
https://doi.org/10.2337/ds16-0026
Published: 01 August 2017
View articletitled, Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Open the PDF for Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes in another window
Journal Articles

Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System

Open Access
S. Christopher Jones, Debra L. Ryan, Valerie S.W. Pratt, Ali Niak, Allen D. Brinker
Journal: Diabetes Spectrum
Diabetes Spectr 2015;28(4):283–288
https://doi.org/10.2337/diaspect.28.4.283
Published: 01 November 2015
View articletitled, Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System
Open the PDF for Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System in another window
Journal Articles

Update on Safety Issues Related to Antihyperglycemic Therapy

Free
Gandahari Rosa A. Carpio, MD, Vivian A. Fonseca, MD, FRCP
Journal: Diabetes Spectrum
Diabetes Spectr 2014;27(2):92–100
https://doi.org/10.2337/diaspect.27.2.92
Published: 01 May 2014
View articletitled, Update on Safety Issues Related to Antihyperglycemic Therapy
Open the PDF for Update on Safety Issues Related to Antihyperglycemic Therapy in another window
Journal Articles

Optimizing the Clinical Use of the GLP-1 Receptor Agonist Exenatide Once Weekly

Free
Susan LaRue, RD, CDE, Steven C. Brunell, PhD, Mary Beth DeYoung, PhD, Laura B. Hieronymus, MSEd, RN, BC-ADM, CDE, Edward Bezarro, RPh, Steve Chen, MD
Journal: Diabetes Spectrum
Diabetes Spectr 2013;26(1):46–52
https://doi.org/10.2337/diaspect.26.1.46
Published: 01 February 2013
View articletitled, Optimizing the Clinical Use of the GLP-1 Receptor Agonist Exenatide Once Weekly
Open the PDF for Optimizing the Clinical Use of the GLP-1 Receptor Agonist Exenatide Once Weekly in another window
Journal Articles

Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview

Free
Carolyn Robertson, APRN, MSN, ACNS-BC, BC-ADM, CDE
Journal: Diabetes Spectrum
Diabetes Spectr 2011;24(1):26–35
https://doi.org/10.2337/diaspect.24.1.26
Published: 01 February 2011
View articletitled, Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview
Open the PDF for Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview in another window
Journal Articles

Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes

Free
Priscilla Hollander, MD
Journal: Diabetes Spectrum
Diabetes Spectr 2007;20(3):159–165
https://doi.org/10.2337/diaspect.20.3.159
Published: 01 July 2007
View articletitled, Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes
Open the PDF for Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes in another window
Journal Articles

Expanded Use of Exenatide in the Management of Type 2 Diabetes

Free
Linda E. John, PharmD, Michael P. Kane, PharmD, FCCP, BCPS, Robert S. Busch, MD, FACE, Robert A. Hamilton, PharmD
Journal: Diabetes Spectrum
Diabetes Spectr 2007;20(1):59–63
https://doi.org/10.2337/diaspect.20.1.59
Published: 01 January 2007
View articletitled, Expanded Use of Exenatide in the Management of Type 2 Diabetes
Open the PDF for Expanded Use of Exenatide in the Management of Type 2 Diabetes in another window
Journal Articles

Use of Exenatide in Patients With Type 2 Diabetes

Free
Robert Hood, MD, Virginia Valentine, CNS, BC-ADM, CDE, Susanna Mac, MD, PhD, William H Polonsky, PhD, CDE
Journal: Diabetes Spectrum
Diabetes Spectr 2006;19(3):181–186
https://doi.org/10.2337/diaspect.19.3.181
Published: 01 July 2006
View articletitled, Use of Exenatide in Patients With Type 2 Diabetes
Open the PDF for Use of Exenatide in Patients With Type 2 Diabetes in another window